{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:00:21Z","timestamp":1791478821044,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vancomycin is a glycopeptide antibiotic of choice for treating serious Gram-positive bacterial infections, including methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA). However, its therapeutic efficacy and risk of nephrotoxicity are closely related to maintaining specific serum concentration levels. Liver transplant recipients (LTRs) require precise therapeutic drug monitoring (TDM) due to altered pharmacokinetics. This study compares the accuracy and precision of two vancomycin measurement methods\u2014chemiluminescent microparticle immunoassay (CMIA) and high-performance liquid chromatography (HPLC) in LTRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The cross-sectional study was conducted over 11\u00a0months at the Abu-Ali Sina Solid Organ Transplant Hospital in Shiraz, Iran. The study included 34 adult LTRs on vancomycin treatment, excluding those with hypersensitivity, chronic kidney disease, burn injuries, or receiving phenytoin. Blood samples were collected at different intervals post-vancomycin administration and analyzed using both CMIA and HPLC methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HPLC demonstrated superior accuracy and precision in measuring vancomycin concentrations, particularly in identifying patients with vancomycin-induced nephrotoxicity. Significantly higher trough (p-value: 0.026) and intermediate (p-value: 0.49) concentrations were detected by HPLC in patients experiencing nephrotoxicity, whereas CMIA did not show significant differences between groups. Pharmacokinetic variables such as half-life (p-value: 0.024) and AUC (p-value:0.037), measured by HPLC, were significantly different between LTRs with and without nephrotoxicity, which was not observed with CMIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HPLC is more sensitive and reliable than CMIA for measuring vancomycin levels in LTRs, which is critical for optimizing vancomycin therapy and preventing adverse effects. The research suggests that HPLC should be the preferred method for vancomycin TDM in LTRs and further multicenter studies are recommended to validate these results.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1516339","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:14:35Z","timestamp":1748931275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic vancomycin monitoring: a comparative analysis of high-performance liquid chromatography and chemiluminescent microparticle immunoassay methods in liver transplant recipients"],"prefix":"10.3389","volume":"16","author":[{"given":"Soha","family":"Azadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Soroush","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soliman","family":"Mohammadi-Samani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Ghasemiyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Geramizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Nikoupour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Vazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Shafiekhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/molecules30051062","article-title":"The development and validation of a simple HPLC-UV method for the determination of vancomycin concentration in human plasma and application in critically ill patients","volume":"30","author":"Aboelezz","year":"2025","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00216-009-2948-9","article-title":"Determination of vancomycin in human plasma using high-performance liquid chromatography with fluorescence detection","volume":"395","author":"Abu-Shandi","year":"2009","journal-title":"Anal. Bioanal. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e002800","DOI":"10.1128\/aac.00280-17","article-title":"Pharmacokinetic assessment of vancomycin loading dose in critically ill patients","volume":"61","author":"\u00c1lvarez","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-2334-14-183","article-title":"Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies","volume":"14","author":"Barriere","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1128\/aac.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","article-title":"Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database","volume":"34","author":"Cano","year":"2012","journal-title":"Clin. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/FTD.0b013e3182a458bc","article-title":"Development and validation of a new ultra-performance liquid chromatographic method for vancomycin assay in serum and its application to therapeutic drug monitoring","volume":"36","author":"Cao","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/jac\/dkaa150","article-title":"Precision and accuracy of commercial assays for vancomycin therapeutic drug monitoring: evaluation based on external quality assessment scheme","volume":"75","author":"Chen","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20499361221140368","DOI":"10.1177\/20499361221140368","article-title":"Vancomycin area under the curve\/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit","volume":"9","author":"Chen","year":"2022","journal-title":"Ther. Adv. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.3390\/molecules27217319","article-title":"An overview of analytical methodologies for determination of vancomycin in human plasma","volume":"27","author":"Cheng","year":"2022","journal-title":"Molecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/j.1875-9114.1986.tb03471.x","article-title":"Vancomycin: an update","volume":"6","author":"Cheung","year":"1986","journal-title":"Pharmacotherapy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/medicina59040691","article-title":"Evaluating the nephrotoxicity of area-under-the-curve-based dosing of vancomycin with concomitant antipseudomonal beta-lactam antibiotics: a systematic review and meta-analysis","volume":"59","author":"Chiu","year":"2023","journal-title":"Med. Kaunas."},{"key":"B13","doi-asserted-by":"publisher","first-page":"100817","DOI":"10.1016\/j.trre.2023.100817","article-title":"Immunosuppression for older liver transplant recipients","volume":"38","author":"De Simone","year":"2024","journal-title":"Transpl. Rev. Orl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4155\/bio-2018-0310","article-title":"An ultra-performance liquid chromatography-tandem mass spectrometry method to quantify vancomycin in human serum by minimizing the degradation product and matrix interference","volume":"11","author":"Fan","year":"2019","journal-title":"Bioanalysis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1128\/aac.24.2.216","article-title":"Evaluation of an automated fluorescence polarization immunoassay for vancomycin","volume":"24","author":"Filburn","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/ccm.0000000000004326","article-title":"Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis","volume":"48","author":"Flannery","year":"2020","journal-title":"Crit. Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4103\/1735-5362.301337","article-title":"A simple and validated HPLC method for vancomycin assay in plasma samples: the necessity of TDM center development in Southern Iran","volume":"15","author":"Ghasemiyeh","year":"2020","journal-title":"Res. Pharm. Sci."},{"key":"B18","first-page":"1","article-title":"Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation (HSCT)","volume":"7","author":"Ghehi","year":"2013","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/bmc.3631","article-title":"Comparison of a high-performance liquid chromatography method for quantification of carbamazepine with chemiluminescent microparticle immunoassay","volume":"30","author":"Guerrero Gardu\u00f1o","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/chromsci\/bms128","article-title":"Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid","volume":"51","author":"Hagihara","year":"2013","journal-title":"J. Chromatogr. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e9932","DOI":"10.1002\/rcm.9932","article-title":"Development and validation of a rapid HPLC-MS\/MS method for simultaneous determination of cyclosporine A and tacrolimus in whole blood for routine therapeutic drug monitoring in organ transplantation","volume":"39","author":"Han","year":"2025","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"B22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s101560050018","article-title":"Study of the pharmacokinetics of vancomycin in patients with impaired liver function","volume":"5","author":"Harada","year":"1999","journal-title":"J. Infect. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1128\/aac.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1345\/aph.1R158","article-title":"The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis","volume":"46","author":"Horey","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/pathogens13010076","article-title":"Biofilm producing methicillin-resistant Staphylococcus aureus (MRSA) infections in humans: clinical implications and management","volume":"13","author":"Kaushik","year":"2024","journal-title":"Pathogens"},{"key":"B26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor's new clothes: PRospective observational evaluation of the association between initial VancomycIn exposure and failure rates among ADult HospitalizEd patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchromb.2018.04.028","article-title":"Simultaneous determination of cyclosporine and tacrolimus in human whole blood by ultra-high performance liquid chromatography tandem mass spectrometry and comparison with a chemiluminescence microparticle immunoassay","author":"Mei","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/lt.26517","article-title":"Pharmacokinetic and pharmacodynamic considerations of antibiotics and antifungals in liver transplantation recipients","volume":"29","author":"Morales Junior","year":"2023","journal-title":"Liver Transpl."},{"key":"B31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.46542\/pe.2024.243.197203","article-title":"Vancomycin bioanalysis for TDM services by using immunoassay and HPLC: a scoping review","volume":"24","author":"Ningrum","year":"2024","journal-title":"Pharm. Educ."},{"key":"B32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/17425247.2025.2459756","article-title":"Potential of nanocarrier-mediated delivery of vancomycin for MRSA infections","volume":"22","author":"Nyandoro","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"B33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cca.2014.12.012","article-title":"Novel LC-MS\/MS method for plasma vancomycin: comparison with immunoassays and clinical impact","volume":"441","author":"Oyaert","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00007691-199908000-00003","article-title":"Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients","volume":"21","author":"Polard","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.3748\/wjg.v24.i38.4311","article-title":"Management of bacterial and fungal infections in end stage liver disease and liver transplantation: current options and future directions","volume":"24","author":"Righi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1128\/aac.32.6.848","article-title":"Vancomycin pharmacokinetics in patients with various degrees of renal function","volume":"32","author":"Rodvold","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000347037","article-title":"A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure","volume":"3","author":"Roy","year":"2013","journal-title":"Cardiorenal Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system Pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health-System Pharm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"103869","DOI":"10.1016\/j.bjid.2024.103869","article-title":"Comparison of vancomycin assays in patients undergoing hemodialysis","volume":"28","author":"Scribel","year":"2024","journal-title":"Braz J. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1089\/sur.2023.055","article-title":"Pharmacokinetic and pharmacodynamic considerations of novel antibiotic agents for pediatric infections: a narrative review","volume":"24","author":"Shafiekhani","year":"2023","journal-title":"Surg. Infect. (Larchmt)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00134-013-2909-9","article-title":"Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis","volume":"39","author":"Shimamoto","year":"2013","journal-title":"Intensive Care Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0046021","DOI":"10.1128\/Spectrum.00460-21","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in pediatric liver transplant recipients","volume":"9","author":"Shoji","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/phar.2279","article-title":"Falsely elevated vancomycin concentrations in a patient not receiving vancomycin","volume":"39","author":"Tsoi","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","article-title":"Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"Ye","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/clinchem\/35.7.1504","article-title":"Clinical performance of the EMIT vancomycin assay","volume":"35","author":"Yeo","year":"1989","journal-title":"Clin. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/ftd.0000000000000750","article-title":"Therapeutic drug monitoring coupled with bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis","volume":"42","author":"Zhang","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"B48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/ftd.0000000000000256","article-title":"Development and validation of a simple and rapid UPLC-MS assay for valproic acid and its comparison with immunoassay and HPLC methods","volume":"38","author":"Zhao","year":"2016","journal-title":"Ther. Drug Monit."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1516339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:14:36Z","timestamp":1748931276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1516339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":48,"alternative-id":["10.3389\/fphar.2025.1516339"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1516339","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"article-number":"1516339"}}